SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals completes USFDA inspection for API-III Facility at Karakhadi

22 Mar 2025 Evaluate

Alembic Pharmaceuticals has successfully completed the United States Food and Drug Administration (USFDA) inspection for its API-III Facility located at Karakhadi. This was a scheduled GMP inspection and was successfully completed without any Form 483 observation. The inspection was conducted from March 17, 2025 to March 21, 2025. 

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.


Alembic Pharma Share Price

772.85 -12.10 (-1.54%)
20-Apr-2026 12:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1672.80
Dr. Reddys Lab 1238.00
Cipla 1238.25
Zydus Lifesciences 942.95
Lupin 2333.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×